An estimated 15,000 mobile healthcare applications are available for healthcare workers and consumers, and the number of mobile-device users who've downloaded one of those apps doubled over the past year. However, even with all of that astounding innovation and activity, what's been tried and true has also retained value in this fast-moving world of today's smartphones and slick Web-enabled tablet computers.
Epocrates, initially a drug reference tool, and one of the few remaining healthcare information technology survivors of the implosion of the dot-com bubble more than a decade ago, was chosen—far and away—as the top choice in Modern Healthcare's inaugural Most Important Mobile Healthcare Apps competition, according to a survey of our readers, with help from members of two leading healthcare information technology organizations. Those groups are the Association of Medical Directors of Information Systems, a professional association of physician informaticists, and the College of Healthcare Information Management Executives, a professional association of hospital chief information officers.
Read the full story: http://bit.ly/TXVbWb
Source: ModernHealthcare.com
Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH
December 6th 2023ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Read More
Humana Report Shows Benefits of Value-Based Care for Patients, Physicians
December 6th 2023Patients seen at value-based care clinics received more preventive screenings and had lower risks of hospitalization and emergency room visits, according to Humana’s 10th annual value-based care report.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More